

| Catalog No. | CB011011 |
|---|---|
| Description |
Recombinant Dog CD22 Protein, C-Fc (CB011011) expressed in Mammalian Cells, spanning Ser55-Arg718. Purity: >90% by SDS-PAGE.
Highlights
|
| Expression system | Mammalian cells |
| Accession | XP_025277290.1 |
| Protein length | Ser55-Arg718 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Species | Canis lupus dingo (Dog) |
| Nature | Recombinant |
| Target | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14 |
| Endotoxin level | <0.1 EU/ug as determined by LAL method. |
| Purity | >90% as determined by SDS-PAGE. |
| Predicted molecular weight | 103.41 kDa |
| Form | Lyophilized |
| Storage buffer | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Shipping | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14 |
| Background | B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366 |
| Note | For research use only |



Contact us for custom quotes, bulk requests and any other issues.
Mail: [email protected]
Quick access
Contact Us
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский